Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately
MarketBeat
Roivant Sciences (NASDAQ:ROIV) said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered commercial launch.
Matt Gline, Roivant’s CEO, called the approval a significant milestone for patients w
NASDAQ:ROIV